Omicron variant escapes therapeutic mAbs contrary to eight prior main VOC
Omicron variant escapes therapeutic mAbs contrary to eight prior main VOC
Abstract Monocolonal antibodies (mAbs) are currently used for active immunization of COVID-19 in immunocompromised patients. We herein show that in spite there are variations in susceptibility to available mAbs that are authorized for clinical use in France tested on the original B.1.1 virus and 9 variants of concern or of interest, the cocktail casirivimab/imdevimab (REGN-CoV-2) showed a major synergistic effect. However, none of the four mAbs either alone or in combination neutralized the new Omicron variant. Our data strongly warrant a reinforcement of protective measures against infection for immunocompromised patients.
Colson Philippe、Moal Val¨|rie、Scola Bernard La、Bancod Audrey、Boschi C¨|line
Aix-Marseille UniversityAix-Marseille UniversityAix-Marseille UniversityAix-Marseille UniversityAix-Marseille University
医药卫生理论医学研究方法药学
Colson Philippe,Moal Val¨|rie,Scola Bernard La,Bancod Audrey,Boschi C¨|line.Omicron variant escapes therapeutic mAbs contrary to eight prior main VOC[EB/OL].(2025-03-28)[2025-06-09].https://www.biorxiv.org/content/10.1101/2022.01.03.474769.点此复制
评论